Important Notice
The information regarding the impact of this issuance on the company's main financial indicators does not constitute a profit forecast, and investors should not base their investment decisions on it. The company will not bear compensation for losses incurred by investors based on this information. The company reminds investors that the measures to compensate for diluted returns do not guarantee future profits.
According to relevant regulations from the State Council and the China Securities Regulatory Commission, Qingdao Impulse Health Technology Co., Ltd. (hereinafter referred to as "the Company") has analyzed the potential impact of this issuance on common shareholders' equity and immediate returns. The Company has developed measures to compensate for the dilution of immediate returns following this issuance.
I. Impact of the Issuance on Main Financial Indicators
(1) Basic Assumptions
- It is assumed that there are no significant adverse changes in the macroeconomic environment, industrial policies, industry development status, and product market conditions.
- The issuance is expected to be completed by October 2026, and the Company and all members of the board guarantee the truthfulness, accuracy, and completeness of the disclosed information, with no false records, misleading statements, or significant omissions.
- The estimated issuance quantity is 44.339092 million shares (not exceeding 30% of the Company's total share capital of 147.796976 million shares before the issuance), subject to the number of shares approved by the CSRC.
- According to the Company's disclosed 2025 annual report, the net profit attributable to the parent company for 2025 is 62.9886 million yuan, and the net profit attributable to the parent company after deducting non-recurring gains and losses is 55.4097 million yuan. The net profit attributable to common shareholders of the parent company for 2026 is estimated under three scenarios: (1) equal to 2025; (2) a 10% increase from 2025; (3) a 20% increase from 2025. This assumption is only for calculating the impact of the issuance on immediate returns and does not represent the Company's judgment on the 2026 operating situation or trends, nor does it constitute a profit forecast.
- The impact of the funds raised on the Company's operations and financial status (such as financial expenses and investment income) after the issuance is not considered.
- When calculating the total share capital and earnings per share after the issuance, only the above assumptions regarding total share capital are considered, without accounting for other potential equity changes.
(2) Impact on Main Financial Indicators
Based on the above assumptions, the Company has calculated the impact of the stock issuance on its main financial indicators, as follows:
| Project | 2025 Year | 2026 Year | Before Issuance | After Issuance |
|---|---|---|---|---|
| Total Share Capital (10,000 shares) | 14,779.70 | 14,779.70 | 14,779.70 | 19,213.61 |
| Net Profit Attributable to Parent Company | 6,298.86 | 6,298.86 | 6,298.86 | 6,298.86 |
| Net Profit Attributable to Parent Company (after deducting non-recurring gains and losses) | 5,540.97 | 5,540.97 | 5,540.97 | 5,540.97 |
| Basic Earnings Per Share (yuan/share) | 0.4298 | 0.4298 | 0.4298 | 0.4092 |
| Diluted Earnings Per Share (yuan/share) | 0.4298 | 0.4298 | 0.4298 | 0.4092 |
| Basic Earnings Per Share (after deducting non-recurring gains and losses) (yuan/share) | 0.3781 | 0.3781 | 0.3781 | 0.3600 |
| Diluted Earnings Per Share (after deducting non-recurring gains and losses) (yuan/share) | 0.3781 | 0.3781 | 0.3781 | 0.3600 |
Note: Basic and diluted earnings per share are calculated according to the "Rules for the Disclosure of Information by Companies Issuing Securities No. 9 - Calculation and Disclosure of Return on Net Assets and Earnings Per Share."